Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CORT and other ETFs, options, and stocks.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
500
Employees500
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
500
Employees500

CORT Key Statistics

Market cap
8.81B
Market cap8.81B
Price-Earnings ratio
95.70
Price-Earnings ratio95.70
Dividend yield
Dividend yield
Average volume
1.09M
Average volume1.09M
High today
$85.34
High today$85.34
Low today
$81.26
Low today$81.26
Open price
$82.06
Open price$82.06
Volume
2.11M
Volume2.11M
52 Week high
$117.33
52 Week high$117.33
52 Week low
$49.00
52 Week low$49.00

Stock Snapshot

With a market cap of 8.81B, Corcept Therapeutics(CORT) trades at $83.76. The stock has a price-to-earnings ratio of 95.70.

On 2025-12-20, Corcept Therapeutics(CORT) stock traded between a low of $81.26 and a high of $85.34. Shares are currently priced at $83.76, which is +3.1% above the low and -1.9% below the high.

The Corcept Therapeutics(CORT)'s current trading volume is 2.11M, compared to an average daily volume of 1.09M.

During the past year, Corcept Therapeutics(CORT) stock moved between $49.00 at its lowest and $117.33 at its peak.

During the past year, Corcept Therapeutics(CORT) stock moved between $49.00 at its lowest and $117.33 at its peak.

CORT News

TipRanks 4d
Corcept Therapeutics falls -8.5%

Corcept Therapeutics (CORT) is down -8.5%, or -$7.40 to $79.90. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and pow...

TipRanks 4d
Hold Rating for Corcept Therapeutics Amid Limited Upside and Market Challenges

Ashwani Verma, an analyst from UBS, has initiated a new Hold rating on Corcept Therapeutics (CORT). Claim 50% Off TipRanks Premium and Invest with Confidence Un...

Analyst ratings

67%

of 6 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.